Table 1.
Patient characteristics
| NAC | No NAC | All | |||||
|---|---|---|---|---|---|---|---|
| All NAC | CR—complete response | SD—stable disease | PD—progressive disease | p value | |||
| Designation of outome | – | pT0N0M0 | pTis-T4aN0M0 | pTanyN+ | All pT-stages | – | |
| No. of patients | 83 | 36 | 35 | 12 | 33 | 116 | |
| Age (mean) | 67 | 66.8 | 69.3 | 0.61 | 75.8 | 69.7 | |
| Age (range) | 39–80 | 39–79 | 39–79 | 58–80 | 57–87 | 39–87 | |
| Gender | 0.91 | ||||||
| Male | 66 (79.5) | 28 (77.8) | 28 (80) | 10 (83.3) | 19 (57.6) | 85 (73.3) | |
| Female | 17 (20.5) | 8 (22.2) | 7 (20) | 2 (16.7) | 14 (42.4) | 31 (26.7) | |
| Clinical stage | 0.04 | ||||||
| cT2 | 63 (75.9) | 32 (88.9) | 24 (68.6) | 7 (58.3) | 23 (69.7) | 86 (74.1) | |
| cT3 | 17 (20.5) | 4 (11.1) | 8 (22.9) | 5 (41.7) | 10 (30.3) | 27 (23.3) | |
| cT4a | 3 (3.6) | 0 | 3 (8.6) | 0 | 0 | 3 (2.6) | |
| No. of NAC-cycles | 0.86 | ||||||
| 1 | 6 (7.2) | 3 (8.3) | 2 (5.7) | 1 (8.3) | |||
| 2 | 9 (10.8) | 1 (2.8) | 6 (17.1) | 2 (16.7) | |||
| 3 | 62 (74.7) | 30 (83.3) | 24 (68.6) | 8 (66.7) | |||
| 4 | 6 (7.2) | 2 (5.6) | 3 (8.6) | 1 (8.3) | |||
| NAC-type | 0.89 | ||||||
| MVAC | 25 (30.1) | 11 (30.5) | 11 (31.4) | 3 (25) | |||
| HD-MVAC | 53 (63.9) | 24 (66.7) | 21 (60) | 8 (66.7) | |||
| Cisplatin-gemzar | 4 (4.8) | 1 (2.8) | 2 (5.7) | 1 (8.3) | |||
| Carboplatin-gemzar | 1 (1.2) | 0 | 1 (2.9) | 0 | |||
Baseline characteristics for all 116 cystectomized patients distributed over subgroups. Statistical analysis was applied on NAC-patients only. There were no statistical differences between NAC-subgroups in age, gender, number of NAC-cycles or NAC-type. NAC-subgroups differed significantly in clinical tumour stage pre-RC (p = 0.04)
NAC neoadjuvant chemotherapy, RC radical cystectomy, HD-MVAC high dose Methorexate, Vinblastine, Adriamycin, Cisplatin